查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984104

In Silico药物发现市场：2026-2032年全球市场预测（按技术平台、治疗领域、分子模式、应用、最终用户和部署模式划分）

In-Silico Drug Discovery Market by Technology Platform, Therapeutic Area, Molecule Modality, Application, End User, Deployment Model - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，In Silico药物发现市场价值将达到 30.3 亿美元，到 2026 年将成长到 33.1 亿美元，到 2032 年将达到 57.5 亿美元，复合年增长率为 9.58%。

主要市场统计数据
基准年 2025 30.3亿美元
预计年份：2026年 33.1亿美元
预测年份 2032 57.5亿美元
复合年增长率 (%) 9.58%

电脑辅助药物发现作为一种组织能力，具有战略重要性，它整合了资料科学、实验检验和营运管治。

In Silico辅助药物发现正从一种简单的辅助手段发展成为现代转化研究的核心支柱，它融合了计算、数据和专业知识，加速药物发现生命週期中的决策过程。本文不仅将该领域定位为一套工具，更将其视为一种综合方法，能够缩短研发週期，提高假设质量，并在研发早期阶段做出更可靠的「做/不做」决策。此外，本文也将电脑辅助方法置于更广泛的研发策略框架下，强调了协调实验检验、法规要求和商业性需求的重要性日益凸显，而非可有可无。

计算方法、基础设施规模和伙伴关係模式的进步如何从根本上重塑药物发现策略和药物发现研究的管治。

In Silico药物发现领域的格局正经历着几项变革性的转变，这些转变从根本上改变了成功的定义及其实现方式。首先，调查方法的融合正在带来更可靠的结果。基于物理的分子模拟正越来越多地与机器学习模型相结合，这些模型能够从公共和专有资料集中学习，从而形成混合方法，既能捕捉机制层面的洞见，又能将预测扩展到大规模化合物库。这种整合需要一种新的跨学科人才团队和工作流程，以协调不同的不确定性因素和检验标准。

本研究评估了 2025 年美国实施的关税措施对电脑辅助药物发现操作中的采购、供应链韧性和实施决策的连锁影响。

2025年的政策环境，特别是美国发起的关税，将对In Silico药物发现生态系统产生多方面的影响，而不仅限于直接采购成本。关税波动将影响关键硬体组件（例如GPU和专用加速器）的可用性和价格，这些组件对于高通量分子模拟和深度学习模型训练至关重要。随着进口关税的提高，采购週期将会延长，从而改变资本预算决策，促使各机构重新评估其运算基础设施的更新週期，并优先考虑工作负载整合和云端迁移，以降低初始投资风险。

可操作的细分情报，用于绘製平台架构、应用程式需求、部署偏好、最终用户优先顺序和治疗领域限制，以便进行有针对性的功能开发。

了解细分市场对于协调技术投资和组织优先事项与多样化的工作流程和特定使用者需求至关重要。必须注意基于技术平台的不同角色，例如计算化学和生物资讯学、高效能运算、机器学习和人工智慧以及分子建模。每个平台细分市场都需要其自身合适的资料工程流程、检验框架和人才库。整合这些平台为混合方法创造了机会，这些方法将基于机制的模拟与数据驱动的预测相结合。

美洲、欧洲、中东和非洲以及亚太地区的能力模式和战略考量决定了实施路径和伙伴关係模式。

区域环境塑造了企业能力的引入和扩展方式，进而影响人才获取、监管预期和伙伴关係生态系统。美洲地区聚集了许多一体化生物製药公司，拥有充满活力的Start-Ups生态系统，有利于快速原型製作、便利的创业投资以及与临床网路的深度合作。这些条件支持雄心勃勃的内部平台和商业性伙伴关係，但同时也要求企业密切关注智慧财产权策略并遵守不断变化的监管准则。

差异化的技术能力、伙伴关係模式和检验方法如何塑造电脑辅助药物发现领域的竞争定位和长期商业性关係。

In Silico药物发现领域的竞争动态并非由单一供应商主导，而是由专业技术供应商、平台整合商和生物製药应用商组成的生态系统所构成，形成一个模组化的价值链。技术供应商透过专有演算法、精心设计的训练资料集以及与实验室自动化系统和电子实验记录本（ELN）系统的整合能力来脱颖而出。一些公司专注于基于物理的模拟和分子建模，而其他公司则强调生成式化学和深度学习方法，从而在药物发现过程的每个阶段创造独特的价值提案。

行业领导者应采取的具体策略和营运重点，以将电脑辅助药物发现从试点阶段扩展到检验和运行的药物发现流程。

产业领导者应采取持续的策略和营运措施，将计算科学的潜力转化为永续的专案成果。首先，建立将计算科学目标与治疗目标和产品组合目标相衔接的管治，确保模型输出能够直接反映在临床前决策中，并确保各团队的评估指标标准化。这种协调一致将减少从先导计画过渡到实用化流程时的阻力，并明确投资重点。

一项透明的混合方法研究通讯协定，结合了专家直接参与、二手文献整合以及多源资料检验，以确保获得稳健且可操作的见解。

本分析的研究方法结合了质性专家对话、结构化二手证据整合以及严格的资料检验通讯协定。关键资讯是透过与计算化学、机器学习、高效能运算操作和监管领域的专家进行半结构化访谈收集的，从而直接洞察了实践中观察到的操作挑战、应用障碍和成功因素。整合这些对话揭示了不同组织类型中通用主题和多样化实践。

综合结论强调，管治、可重复性和实施的柔软性对于从基于计算化学的药物发现计划中实现永续价值至关重要。

总之，In Silico药物发现正日益成熟，成为一项战略能力，需要精心设计的组织架构、灵活的基础设施和严谨的检验方法才能实现可持续的转换价值。混合计算方法、不断演进的伙伴关係模式以及区域部署的实际情况相互作用，既带来了机会，也带来了营运上的复杂性，领导者必须积极应对。那些能够将技术选择与治疗重点相结合、将可重复性和可解释性融入工作流程并采取稳健的采购和部署策略的组织，将获得最大的利益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按技术平台In Silico药物发现市场

  • 计算化学与生物资讯学
  • 高效能运算
  • 机器学习/人工智慧
  • 分子建模

第九章：In Silico药物发现市场：依治疗领域划分

  • 循环系统
  • 中枢神经系统
  • 感染疾病
  • 肿瘤学

第十章：In Silico药物发现市场

  • 低分子化合物
  • 生物製药
    • 单株抗体
    • 双特异性抗体
  • 胜肽
    • 线性胜肽
    • 环肽
  • 寡核苷酸和RNA
    • siRNA
    • mRNA治疗药物

第十一章：In Silico药物发现市场：按应用领域划分

  • ADMET预测
    • 吸收预测
    • 分布预测
    • 排泄预测
    • 代谢预测
    • 毒性预测
  • 先导化合物的鑑定与优化
    • De Novo 设计
    • 基于片段的最佳化
  • 药物药物动力学模型
  • 目标识别与检验
  • 虚拟筛检
    • 基于配体的虚拟筛检
    • 基于结构的虚拟筛检

第十二章：In Silico药物发现市场：依最终使用者划分

  • 学术和研究机构
  • 合约研究机构
  • 製药和生物技术公司

第十三章：In Silico药物发现市场：依开发模式划分

  • 基于云端的
  • 现场

第十四章：In Silico药物发现市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：In Silico药物发现市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：In Silico药物发现市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国In Silico药物发现市场

第十八章：中国In Silico药物发现市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Charles River Laboratories International, Inc.
  • Schrodinger Inc.
  • Certara, Inc.
  • XtalPi by Shenzhen Jingtai Technology Co., Ltd
  • InSilico Medicine
  • Dassault Systemes SE
  • BenevolentAI
  • Recursion Pharmaceuticals
  • Evotec SE
  • Iktos SA
  • WuXi AppTec
  • Envisagenics
  • AbCellera Biologics Inc.
  • Abzena Ltd.
  • Aragen Life Sciences Pvt. Ltd.
  • AstraZeneca PLC
  • BioDuro LLC
  • BioNTech SE
  • Chemical Computing Group ULC
  • ChemPartner PharmaTech Co Ltd
  • Creative Biostructure
  • Curia Global Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenScript Biotech Corporation
  • GlaxoSmithKline plc
  • Ligand Pharmaceuticals Incorporated
  • Merck & Co.
  • Novartis AG
  • Sanofi Group
  • Selvita SA
  • Simulations Plus, Inc.
  • Sygnature Discovery
  • Valo Health, Inc.
  • Viva Biotech Holding Group
Product Code: MRR-2E76C3E47FCA

The In-Silico Drug Discovery Market was valued at USD 3.03 billion in 2025 and is projected to grow to USD 3.31 billion in 2026, with a CAGR of 9.58%, reaching USD 5.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.03 billion
Estimated Year [2026] USD 3.31 billion
Forecast Year [2032] USD 5.75 billion
CAGR (%) 9.58%

Framing the strategic importance of computational drug discovery as an organizational competency that integrates data science, experimental validation, and operational governance

In-silico drug discovery is transitioning from a complementary capability to a central pillar of modern translational research, where computation, data, and domain expertise converge to accelerate decision-making across the discovery lifecycle. This introduction frames the discipline not merely as a set of tools but as an integrated approach that reduces cycle times, elevates hypothesis quality, and enables higher-confidence go/no-go decisions earlier in development. It also situates computational approaches within broader R&D strategies, where alignment with experimental validation, regulatory expectations, and commercial imperatives is increasingly mandatory rather than optional.

The contemporary landscape is characterized by multiple interacting forces: exponential growth in biological data, maturation of machine learning methods tailored to molecular science, and the commoditization of computational capacity through cloud and on-premise environments. These forces have produced an environment in which teams can explore chemical space more systematically, predict ADMET attributes with greater nuance, and triage targets through integrated systems biology perspectives. Consequently, leaders must think beyond isolated proof-of-concept pilots and toward scalable pipelines that embed reproducibility, explainability, and cross-functional handoffs between computational scientists, medicinal chemists, and translational biologists.

Furthermore, the rise of collaborative business models-ranging from vendor partnerships to consortium science-has enabled smaller organizations to access capabilities formerly exclusive to large pharmaceutical companies. This rebalancing of capability access places a premium on orchestration skills: the ability to coordinate data provenance, harmonize modeling outputs, and integrate external service providers in ways that preserve intellectual property while maximizing innovation velocity. In sum, the introduction underscores that in-silico drug discovery is now an organizational competency that requires strategy, governance, and investment in people and infrastructure to deliver sustained value.

How converging advances in computational methods, infrastructure scale, and partnership models are fundamentally reshaping discovery strategies and governance in drug research

The landscape of in-silico drug discovery is being reshaped by several transformative shifts that collectively change what success looks like and how it is achieved. First, methodological convergence is driving more robust outputs: physics-informed molecular simulation is increasingly combined with machine learning models that learn from both public and proprietary datasets, producing hybrid approaches that capture mechanistic insight while scaling predictions across large compound libraries. This convergence demands new interdisciplinary talent profiles and workflows that can reconcile different sources of uncertainty and validation criteria.

Second, infrastructure maturation is enabling operational scalability. Access to high-performance computing resources, whether on-premise clusters or cloud instances optimized for GPU workloads, permits the routine execution of computationally intensive simulations alongside rapid inference pipelines. As a result, organizations are shifting from isolated algorithmic experiments toward continuous integration of predictive models into discovery pipelines, with automated data curation and monitoring to ensure reproducibility.

Third, partnership models are evolving. Strategic alliances between technology vendors, contract research organizations, and biopharma companies are forming to pool domain knowledge, share curated datasets under secure governance, and accelerate target validation. These collaborations are complemented by an ecosystem of specialized service providers who offer modular capabilities-for example, de novo molecular design engines or ligand- and structure-based virtual screening platforms-enabling adopters to compose tailored toolchains.

Finally, regulatory and ethical considerations are becoming central to technology adoption. Expectations around model interpretability, data provenance, and reproducibility are increasing from both internal governance bodies and external stakeholders. Companies that proactively embed auditability and explainability into their computational workflows are better positioned to navigate regulatory scrutiny and build trust with clinical and commercial partners. Taken together, these shifts are not incremental; they reconfigure talent, technology, and governance in ways that favor organizations able to operationalize complex, hybrid computational strategies.

Evaluating how United States tariff measures enacted in 2025 cascade through procurement, supply chain resilience, and deployment decisions across computational drug discovery operations

The policy environment in 2025, including tariff actions originating from the United States, exerts multifaceted effects on in-silico drug discovery ecosystems that extend beyond immediate procurement costs. Tariff shifts influence the availability and pricing of critical hardware components such as GPUs and specialized accelerators, which are essential for high-throughput molecular simulation and deep learning model training. When import duties rise, procurement cycles elongate and capital budgeting decisions shift, prompting organizations to reevaluate refresh cadences for compute infrastructure and to prioritize workload consolidation or cloud migration to mitigate upfront capital exposure.

In addition to hardware considerations, tariffs affect the global software and service supply chain. Many specialized service providers and OEMs operate cross-border manufacturing and support networks; increased trade frictions complicate maintenance contracts, spare parts logistics, and multi-region service level agreements. These operational frictions can lead to higher total cost of ownership for on-premise systems and incentivize a rebalancing toward cloud-based deployments in jurisdictions with more favorable trade arrangements or local data center presence.

Strategically, tariff-driven uncertainty accelerates supply chain diversification and regionalization strategies. Organizations may pursue vendor redundancy, cultivate local partnerships with service providers and contract research organizations, or invest in domestic capacity for key components. Such moves can increase resilience but also raise near-term integration and validation burdens as teams adapt to heterogeneous toolchains and differing support models. Furthermore, tariffs can indirectly influence talent mobility and vendor negotiation dynamics, as suppliers seek to offset margin pressure through service bundling or altered licensing terms.

From a programmatic perspective, tariff impacts underscore the importance of flexible deployment architectures. Hybrid models that combine cloud bursting for peak workloads with on-premise platforms for sensitive or latency-dependent tasks enable teams to respond to both cost volatility and data sovereignty requirements. Decision-makers should therefore incorporate trade-policy scenarios into procurement planning and resilience assessments to ensure computational continuity while managing capital and operating expenditures prudently.

Actionable segmentation intelligence mapping platform architectures, application needs, deployment preferences, end-user priorities, and therapeutic area constraints for targeted capability building

Understanding segmentation is critical to aligning technical investments and organizational priorities with the specific demands of different workflows and users. Based on Technology Platform, attention should be paid to the distinct roles of Computational Chemistry and Bioinformatics versus High Performance Computing, Machine Learning and AI, and Molecular Modeling. Each platform segment requires tailored data engineering pipelines, validation frameworks, and talent mixes, and integrating these platforms creates opportunities for hybrid approaches that blend mechanistic simulation with data-driven prediction.

Based on Application, it is important to distinguish the varied requirements across ADMET Prediction, Lead Identification and Optimization, Pharmacokinetics Modeling, Target Identification and Validation, and Virtual Screening. ADMET Prediction itself decomposes into absorption prediction, distribution prediction, excretion prediction, metabolism prediction, and toxicity prediction, each demanding specialized datasets and domain-specific interpretability. Lead Identification and Optimization encompasses de novo design and fragment-based optimization approaches, which differ in their dependency on generative models versus expert-driven medicinal chemistry heuristics. Virtual Screening bifurcates into ligand-based virtual screening and structure-based virtual screening, with the former favoring cheminformatics and fingerprinting strategies and the latter relying on structural bioinformatics and docking accuracy.

Based on End User, differentiation among Academic and Research Institutes, Contract Research Organizations, and Pharmaceutical and Biotechnology Companies highlights divergent priorities: academic groups may prioritize methodological innovation and open science, contract research organizations emphasize reproducibility and throughput for client deliverables, and industry sponsors focus on regulatory robustness, IP protection, and integration with downstream clinical pipelines. Based on Deployment Model, the choice between Cloud Based and On Premise operations implicates governance, data residency, and cost structures, with hybrid approaches increasingly common to capture the benefits of both models.

Based on Therapeutic Area, the needs of cardiovascular, central nervous system, infectious diseases, and oncology programs vary in terms of target complexity, required assay validation, and tolerance for off-target liabilities. Oncology programs, for instance, often require sophisticated multi-omics integration and biomarker-driven validation, while infectious disease efforts may emphasize rapid screening and pathogen-specific constraint modeling. By mapping platform and application choices to end-user objectives and therapeutic constraints, organizations can more effectively prioritize investments and design fit-for-purpose workflows.

Regional capability patterns and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption pathways and partnership models

Regional context shapes how capabilities are adopted and scaled, influencing talent availability, regulatory expectations, and partnership ecosystems. In the Americas, there is a concentration of integrated biopharma organizations and a vibrant startup ecosystem that favors rapid prototyping, strong access to venture capital, and deep collaborations with clinical networks. These conditions support ambitious internal platforms and commercial partnerships, though they also require careful attention to IP strategy and compliance with evolving regulatory guidance.

In Europe, Middle East & Africa, the region presents a heterogeneous landscape where national research hubs and multinational centers of excellence coexist with growing public-private consortia. Regulatory harmonization efforts and strong emphasis on data protection influence preferred deployment models, often necessitating hybrid on-premise and cloud strategies that respect cross-border data transfer rules. Localized talent pools and strong academic links support method innovation, while strategic partnerships with contract research organizations help bridge scale and operational execution.

In the Asia-Pacific region, rapid expansion of computational capacity, strong government-backed initiatives, and a rising number of technology vendors are creating an environment conducive to large-scale adoption. This region often emphasizes cost-effective cloud solutions and regional data center investments, enabling high-throughput screening and model training at scale. However, differences in regulatory frameworks and language localization can introduce integration challenges, making regional partnerships and local compliance expertise critical for successful program deployment. Across all regions, organizations that align technical choices with local operational realities and partnership opportunities will achieve faster integration and greater resilience.

How differentiated technology capabilities, partnership models, and validation practices shape competitive positioning and long-term commercial relationships in computational discovery

Competitive dynamics in the in-silico drug discovery space are characterized less by single-vendor dominance and more by an ecosystem of specialized technology providers, platform integrators, and biopharma adopters forming modular value chains. Technology vendors differentiate through proprietary algorithms, curated training datasets, and the ability to integrate with laboratory automation and electronic laboratory notebook systems. Some firms emphasize physics-based simulation and molecular modeling, while others lead with generative chemistry and deep learning approaches, creating distinct value propositions for different stages of discovery.

Partnership archetypes include boutique technology providers collaborating with contract research organizations to offer end-to-end services, platform companies licensing core stacks to enterprise teams, and biopharma companies building internal centers of excellence that combine vendor solutions with in-house expertise. Strategic alliances between computational firms and large pharmaceutical organizations are common, and these relationships often center on co-development agreements, data-sharing frameworks, and joint validation studies that demonstrate translational relevance.

Additionally, service providers that can offer validated pipelines and regulatory-grade documentation gain preference among sponsors focused on clinical translation. The ability to demonstrate reproducibility, integrate with legacy IT systems, and meet stringent data governance requirements becomes a competitive differentiator. As a result, companies that invest in interoperability, transparent validation practices, and strong customer support tend to secure longer-term engagements and become preferred partners for enterprise-scale discovery initiatives.

Concrete strategic and operational priorities industry leaders must adopt to scale computational discovery from pilots to validated, production-grade drug discovery pipelines

Industry leaders should enact a coherent set of strategic and operational actions to convert computational promise into durable program outcomes. First, establish governance that ties computational objectives to therapeutic and portfolio goals, ensuring that model outputs feed directly into preclinical decision gates and that evaluation metrics are harmonized across teams. This alignment reduces friction when moving from pilot projects to production pipelines and clarifies investment priorities.

Second, invest in reproducibility and explainability. Embed version control for datasets and models, adopt standardized benchmarking protocols, and document workflows to support regulatory and audit requirements. These practices increase stakeholder confidence and reduce the risk of model drift or unintended biases affecting downstream experiments.

Third, architect flexible infrastructure. Adopt hybrid deployment patterns that allow for cloud elasticity during peak compute demands while preserving secure on-premise environments for sensitive data. Negotiate vendor contracts with clear service level agreements and redundancy provisions to mitigate supply chain disruptions and geopolitical risks.

Fourth, cultivate talent and cross-disciplinary collaboration. Build teams that combine computational scientists with medicinal chemists, pharmacologists, and regulatory experts to ensure that models are realistic, interpretable, and actionable. Provide continuous learning opportunities and create rotational programs that embed computational thinking across discovery functions.

Finally, pursue pragmatic partnerships and data strategies. Prioritize collaborations that provide curated, high-quality datasets with clear governance terms, and consider co-development agreements that share validation burdens. These steps accelerate time-to-impact while preserving strategic control over core IP and decision-critical datasets.

Transparent mixed-methods research protocol combining primary expert engagement, secondary literature synthesis, and multi-source data validation to ensure robust, actionable insights

The research approach underpinning this analysis combined qualitative expert engagement with structured secondary evidence synthesis and rigorous data validation protocols. Primary inputs were gathered through semi-structured interviews with domain experts spanning computational chemistry, machine learning, high-performance computing operations, and regulatory affairs, enabling direct insight into operational challenges, adoption barriers, and success factors observed in practice. These conversations were synthesized to surface common themes and divergent practices across organizational types.

Secondary evidence collection involved curated literature review of peer-reviewed methods papers, conference proceedings, technical white papers from technology providers, and publicly available regulatory guidance to triangulate claims and establish methodological baselines. Emphasis was placed on reproducibility and transparency, with methods and assumptions documented to permit independent review. Data validation employed cross-referencing across multiple independent sources, scenario testing to evaluate sensitivity to infrastructure and policy variables, and plausibility checks to ensure consistency with prevailing technology capabilities.

Limitations were acknowledged and addressed: primary interviews reflect experiential insights from a cross-section of organizations and are not exhaustive, and the pace of technological innovation means that specific tool capabilities evolve rapidly. To mitigate these constraints, the methodology prioritized durable patterns of behavior and structural dynamics over ephemeral product-level specifics. This mixed-methods design yields robust, actionable insights while making explicit the evidentiary basis for conclusions.

Consolidated conclusions emphasizing the necessity of governance, reproducibility, and deployment flexibility to realize sustained value from computational discovery programs

In conclusion, in-silico drug discovery is maturing into a strategic capability that requires deliberate organizational design, flexible infrastructure, and rigorous validation practices to deliver sustained translational value. The interplay of hybrid computational methods, evolving partnership models, and regional deployment realities creates both opportunities and operational complexities that leaders must navigate proactively. Those who align technical choices with therapeutic priorities, embed reproducibility and explainability into workflows, and pursue resilient procurement and deployment strategies will realize the greatest benefit.

Policy dynamics and supply chain pressures underscore the need for adaptable architectures and diversified vendor relationships, while segmentation-aware strategies ensure that investments map to the distinct needs of technology platforms, application types, end users, deployment models, and therapeutic areas. Ultimately, success depends on integrating computational insights into corporate decision-making processes and building cross-functional teams that can translate model outputs into decisive experimental actions. By treating in-silico discovery as a core competency rather than an auxiliary capability, organizations can accelerate the pathway from hypothesis to validated candidate while managing risk and preserving strategic optionality.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Silico Drug Discovery Market, by Technology Platform

  • 8.1. Computational Chemistry & Bioinformatics
  • 8.2. High Performance Computing
  • 8.3. Machine Learning & AI
  • 8.4. Molecular Modeling

9. In-Silico Drug Discovery Market, by Therapeutic Area

  • 9.1. Cardiovascular
  • 9.2. Central Nervous System
  • 9.3. Infectious Diseases
  • 9.4. Oncology

10. In-Silico Drug Discovery Market, by Molecule Modality

  • 10.1. Small Molecules
  • 10.2. Biologics
    • 10.2.1. Monoclonal Antibodies
    • 10.2.2. Bispecific Antibodies
  • 10.3. Peptides
    • 10.3.1. Linear Peptides
    • 10.3.2. Cyclic Peptides
  • 10.4. Oligonucleotides & RNA
    • 10.4.1. siRNA
    • 10.4.2. mRNA Therapeutics

11. In-Silico Drug Discovery Market, by Application

  • 11.1. ADMET Prediction
    • 11.1.1. Absorption Prediction
    • 11.1.2. Distribution Prediction
    • 11.1.3. Excretion Prediction
    • 11.1.4. Metabolism Prediction
    • 11.1.5. Toxicity Prediction
  • 11.2. Lead Identification & Optimization
    • 11.2.1. De Novo Design
    • 11.2.2. Fragment Based Optimization
  • 11.3. Pharmacokinetics Modeling
  • 11.4. Target Identification & Validation
  • 11.5. Virtual Screening
    • 11.5.1. Ligand Based Virtual Screening
    • 11.5.2. Structure Based Virtual Screening

12. In-Silico Drug Discovery Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical & Biotechnology Companies

13. In-Silico Drug Discovery Market, by Deployment Model

  • 13.1. Cloud Based
  • 13.2. On Premise

14. In-Silico Drug Discovery Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. In-Silico Drug Discovery Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. In-Silico Drug Discovery Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States In-Silico Drug Discovery Market

18. China In-Silico Drug Discovery Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Charles River Laboratories International, Inc.
  • 19.6. Schrodinger Inc.
  • 19.7. Certara, Inc.
  • 19.8. XtalPi by Shenzhen Jingtai Technology Co., Ltd
  • 19.9. InSilico Medicine
  • 19.10. Dassault Systemes S.E.
  • 19.11. BenevolentAI
  • 19.12. Recursion Pharmaceuticals
  • 19.13. Evotec SE
  • 19.14. Iktos SA
  • 19.15. WuXi AppTec
  • 19.16. Envisagenics
  • 19.17. AbCellera Biologics Inc.
  • 19.18. Abzena Ltd.
  • 19.19. Aragen Life Sciences Pvt. Ltd.
  • 19.20. AstraZeneca PLC
  • 19.21. BioDuro LLC
  • 19.22. BioNTech SE
  • 19.23. Chemical Computing Group ULC
  • 19.24. ChemPartner PharmaTech Co Ltd
  • 19.25. Creative Biostructure
  • 19.26. Curia Global Inc.
  • 19.27. F. Hoffmann-La Roche Ltd.
  • 19.28. GenScript Biotech Corporation
  • 19.29. GlaxoSmithKline plc
  • 19.30. Ligand Pharmaceuticals Incorporated
  • 19.31. Merck & Co.
  • 19.32. Novartis AG
  • 19.33. Sanofi Group
  • 19.34. Selvita S.A.
  • 19.35. Simulations Plus, Inc.
  • 19.36. Sygnature Discovery
  • 19.37. Valo Health, Inc.
  • 19.38. Viva Biotech Holding Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY & BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY & BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY & BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING & AI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING & AI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING & AI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LINEAR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LINEAR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MRNA THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MRNA THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MRNA THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 244. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 246. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 250. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 251. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 253. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 255. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 283. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 285. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 286. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 290. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 292. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 293. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 294. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 296. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 298. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 299. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY OLIGONUCLEOTIDES & RNA, 2018-2032 (USD MILLION)
  • TABLE 303. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADME